Intragraft DepTOR and transplant rejection
Intragraft DepTOR and transplant rejection
批准号:
9331928
负责人:
David M. Briscoe
金额:
$22.13万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-15 至 2018-12-31
关键词:
AcuteAddressAdhesivesAdipose tissueAllogenicAllograftingAlpha CellAnatomyBindingBiologicalBiologyCD4 Positive T LymphocytesCardiacCell Adhesion MoleculesCell CommunicationCellsCharacteristicsChronicClinicalCollaborationsDataDevelopmentEndothelial CellsEnsureEventEvolutionExcisionExploratory/Developmental Grant for Diagnostic Cancer ImagingFRAP1 geneFutureGraft RejectionGraft SurvivalImmuneImmune responseIn VitroInflammationInflammatoryInflammatory ResponseInjuryKnock-in MouseKnock-outKnockout MiceLaboratoriesLeukocytesLifeLocationLoxP-flanked alleleMAP Kinase GeneModelingMolecularMusMuscle CellsOrgan TransplantationOutcomePathway interactionsPharmacologyPhenotypeProcessProteinsPublishingReagentRecruitment ActivityReportingResearchResearch ProposalsResourcesRoleSTAT1 geneSavingsSignal TransductionSmall Interfering RNASolidSuggestionT-LymphocyteTestingTimeTransgenic MiceTransgenic OrganismsTranslatingTransplantationUbiquitinationVascular Endothelial Cellallograft rejectionangiogenesisbasecancer cellcell typechemokineclinically relevantcohesiongenetic regulatory proteinheart allograftimmunogenicityimmunoregulationin vitro Assayin vivoin vivo Modelisoimmunityknock-downnovelresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
An increasing body of evidence indicates that the state of activation, phenotype and functional response of
the microvasculature to alloimmune injury creates an intragraft microenvironment that both initiates and
sustains the progression of allograft rejection. The unique anatomic location of the graft endothelial cell (EC)
ensures that it is a target of the alloimmune response, and characteristic phenotypes either augment or
inhibit interactions with immune cells. We recently identified DepTOR as a cell intrinsic mTOR-binding
partner that modulates mTOR, MAPK and STAT-induced signaling in microvascular EC. In addition, we
found that it is potent to regulate activation responses, angiogenesis and EC-dependent mechanisms of
inflammation in vitro. These observations allowed us to conclude that the removal of its negative/regulatory
effects are a mechanistic component of the EC pro-inflammatory phenotype. Our findings also suggest that
augmented levels of expression and/or function of DepTOR may inhibit intragraft EC activation and their
immunogenicity to sustain immunoregulation in vivo. However, formal testing of all these possibilities
requires models in which DepTOR expression may be regulated in vivo selectively within allografts post
transplantation. In this R21 proposal, we plan to develop and use novel DepTOR transgenic mice as donors
of cardiac allografts in well-established models in vivo. We will also use cultured EC from transgenic mice
for mechanistic studies in vitro. In this manner, we will be able to evaluate whether DepTOR is functional
within allografts to promote long-term graft survival, and whether it effects are dependent on its ability to
regulate EC-dependent mechanisms of rejection. Our central hypothesis is that cell intrinsic expression of
DepTOR within the graft is immunomodulatory and regulates EC activation responses, EC-dependent
interactions with CD4+ T cells and acute and chronic rejection. We will test this hypothesis in two specific
aims in which we will 1), determine the function of DepTOR within the graft, and its association with acute
and chronic allograft rejection in vivo, and 2), determine the function of DepTOR in EC-dependent
mechanisms of alloimmunity. Collectively, our proposed studies are novel and address clinically relevant
questions and our approach provides for cohesiveness to translate in vitro findings into relevant transplant
models in vivo. These exploratory studies will, for the first time, define a mechanism whereby the
expression of a regulatory protein within the transplanted organ itself may be a determinant of the
phenotype and outcome of the rejection process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing Transplantation Outcomes in Children
-
批准号:10282915
-
项目类别:
-
资助金额:$234.14万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Advancing Transplantation Outcomes in Children
-
批准号:10483207
-
项目类别:
-
资助金额:$244.19万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Advancing Transplantation Outcomes in Children
-
批准号:10647772
-
项目类别:
-
资助金额:$262.35万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Neuropilin-2 in Alloimmunity
-
批准号:10577824
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2020
-
负责人:David M. Briscoe
-
依托单位:
Neuropilin-2 in Alloimmunity
-
批准号:10355442
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2020
-
负责人:David M. Briscoe
-
依托单位:
Role of DEPTOR in T Cell Activation and Alloimmunity
-
批准号:10062851
-
项目类别:
-
资助金额:$70.8万
-
财政年份:2017
-
负责人:David M. Briscoe
-
依托单位:
Role of DEPTOR in T Cell Activation and Alloimmunity
-
批准号:10302288
-
项目类别:
-
资助金额:$57.53万
-
财政年份:2017
-
负责人:David M. Briscoe
-
依托单位:
Function of DepTOR in T Cell Activation and Alloimmunity
-
批准号:8785808
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2014
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8239118
-
项目类别:
-
资助金额:$49.9万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Role of T cell Specific Adaptor Protein in Alloimmunity
-
批准号:8190975
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Role of T cell Specific Adaptor Protein in Alloimmunity
-
批准号:8318083
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8580190
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8385531
-
项目类别:
-
资助金额:$47.88万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8960323
-
项目类别:
-
资助金额:$66.61万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
NOVEL IN VIVO MODEL OF CHRONIC ALLOGRAFT REJECTION
-
批准号:8116409
-
项目类别:
-
资助金额:$26.03万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
Angiogenesis and Chronic Rejection
-
批准号:8093958
-
项目类别:
-
资助金额:$33.37万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
NOVEL IN VIVO MODEL OF CHRONIC ALLOGRAFT REJECTION
-
批准号:7983388
-
项目类别:
-
资助金额:$21.47万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:6919117
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:6781893
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:7078622
-
项目类别:
-
资助金额:$39.55万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
海外基金